TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Andres Forero-TorresTranslational Breast Cancer Research Consortium (TBCRC)

Abstract

Tigatuzumab (TIG), an agonistic anti-DR5 antibody, triggers apoptosis in DR5(+) human tumor cells without crosslinking. TIG has strong in vitro/in vivo activity against basal-like breast cancer cells enhanced by chemotherapy agents. This study evaluates activity of TIG and chemotherapy in patients with metastatic triple-negative breast cancer (TNBC). Randomized 2:1 phase II trial of albumin-bound paclitaxel (nab-PAC) ± TIG in patients with TNBC stratified by prior chemotherapy. Patients received nab-PAC weekly × 3 ± TIG every other week, every 28 days. Primary objective was within-arm objective response rate (ORR). Secondary objectives were safety, progression-free survival (PFS), clinical benefit, and TIG immunogenicity. Metastatic research biopsies were required. Among 64 patients (60 treated; TIG/nab-PAC n = 39 and nab-PAC n = 21), there were 3 complete remissions (CR), 8 partial remissions (PR; 1 almost CR), 11 stable diseases (SD), and 17 progressive diseases (PD) in the TIG/nab-PAC arm (ORR, 28%), and no CRs, 8 PRs, 4 SDs, and 9 PDs in the nab-PAC arm (ORR, 38%). There was a numerical increase in CRs and several patients had prolonged PFS (1,025+, 781, 672, 460, 334) in the TIG/nab-PAC arm. Grade 3 toxicities were 28% and...Continue Reading

References

Aug 30, 2000·Nature·C M PerouD Botstein
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Jan 30, 2004·Cancer Immunology, Immunotherapy : CII·Klaus-Michael Debatin
Apr 13, 2004·Oncogene·Klaus-Michael Debatin, Peter H Krammer
May 25, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jan J KoornstraJan H Kleibeuker
Aug 24, 2006·Genome Biology·Victor SolovyevDenis Vorobyev
May 17, 2007·Breast Cancer Research : BCR·Anita LangerødStefanie S Jeffrey
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Feb 29, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A YadaK Fujiwara
Nov 8, 2008·Nature Reviews. Drug Discovery·Avi Ashkenazi
Mar 18, 2009·Bioinformatics·Cole TrapnellSteven L Salzberg
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William J GradisharPaul Bhar
Mar 2, 2010·Cancer Biotherapy & Radiopharmaceuticals·Andres Forero-TorresMansoor Saleh
Mar 4, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey WiezorekJonathan Graves
Oct 29, 2010·Genome Biology·Simon Anders, Wolfgang Huber
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
Jan 7, 2011·The New England Journal of Medicine·Joyce O'ShaughnessyCharles Bradley
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Sep 9, 2011·Breast Cancer Research and Treatment·Patsy G OliverDonald J Buchsbaum
Sep 15, 2011·Breast Cancer Research and Treatment·Angelina I Londoño-JoshiDonald J Buchsbaum
Dec 1, 2011·Genome Research·Jason GertzRichard M Myers
Aug 9, 2012·Cancer Informatics·Xi ChenJennifer A Pietenpol
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Oct 27, 2012·Clinical Breast Cancer·Emilia MontagnaMarco Colleoni
Feb 19, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ingrid A MayerJennifer A Pietenpol

❮ Previous
Next ❯

Citations

May 28, 2016·Journal of Nanobiotechnology·Ewelina PiktelRobert Bucki
Jul 28, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Anita K BakraniaSnehal S Patel
May 9, 2014·Clinical Breast Cancer·Stefan Glück
Feb 25, 2014·Cancer Treatment Reviews·Christine MegerdichianSara A Hurvitz
Jan 10, 2018·Frontiers in Immunology·Isabel Corraliza-GorjónLeonor Kremer
Mar 24, 2020·Nature Reviews. Clinical Oncology·Benedito A Carneiro, Wafik S El-Deiry
Mar 28, 2017·Experimental Hematology & Oncology·Adam Brufsky
Mar 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aditya BardiaLinda T Vahdat
Feb 12, 2019·Expert Review of Precision Medicine and Drug Development·Marie D Ralff, Wafik S El-Deiry
Mar 16, 2018·Cancer Metastasis Reviews·Xun YuanGen Sheng Wu
Nov 11, 2015·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Harrison KimKurt R Zinn
Feb 16, 2021·EMBO Molecular Medicine·Tanmoy MondalJogender Tushir-Singh
Apr 27, 2021·Expert Opinion on Biological Therapy·Patrick M DillonLawrence G Lum
Jul 25, 2021·Journal for Immunotherapy of Cancer·Shujing WangZhi Yang
Jan 30, 2018·ACS Nano·Pedro P G GuimarãesMichael J Mitchell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis